Results 91 to 100 of about 349 (107)

Cagrilintide-semaglutide (CagriSema) as an add-on to basal insulin in adults with type 2 diabetes (REIMAGINE 3): a randomised, double-blind, placebo-controlled, multicentre, phase 3 study.

Lancet, The
Francesco Giorgino, Julio Rosenstock, Klara R Klein   +2 more
exaly   +2 more sources

Advancing Diabetes Management and Glycemic Control While Exploring CagriSema’s Impact on Obesity Management

Cardiology in Review
Diabetes is a complex metabolic disorder affecting over 37 million people in the United States. Without proper management, diabetes can lead to a myriad of complications, including cardiovascular disease, kidney failure, and vision loss. Obesity is a major contributor to type 2 diabetes, but genetic and physiological factors make weight loss difficult,
Somar, Hadid, William H, Frishman, Wilbert S, Aronow   +2 more
openaire   +2 more sources

Maximizing weight loss with cagrisema: a systematic review and GRADE-assessed meta-analysis of randomized controlled trials.

Naunyn-Schmiedeberg's Archives of Pharmacology
Amna Rehman, Muhammad Huzaifa Khattak
exaly   +2 more sources

Appraisal of Cagrisema for Treatment of Obesity and Type 2 Diabetes

Journal of Aging Science and Gerontology
exaly   +2 more sources

763-P: CagriSema Improves Insulin Sensitivity in Diet-Induced Obese Rats

Diabetes
Introduction & Objective: CagriSema (CS), a combination of the long-acting analogues of amylin (cagrilintide) and glucagon-like peptide-1 (semaglutide), is in clinical development for treatment of obesity and type 2 diabetes. Rodent studies have shown that CS treatment results in weight loss.
ANNA SECHER, CHRISTIAN L. BRAND, KIRSTEN RAUN   +2 more
openaire   +1 more source

A-94 | Efficacy and Safety of CagriSema compared with Semaglutide or Placebo: A Systemic Review and Updated Meta Analysis of Randomized Controlled Trials

Journal of the Society for Cardiovascular Angiography & Interventions
Himat ALI Faiaz, Ahmad Ahmad khan
exaly   +2 more sources

CagriSema Versus Semaglutide Monotherapy or Placebo for Obesity: A Systematic Review and Meta-Analysis of Randomized Controlled Trials with GRADE Assessment

The American Journal of Cardiology
The obesity epidemic is a major health burden that enhances susceptibility to a broad spectrum of metabolic-associated comorbidities, ranging from fatty liver disease and endocrine dysfunction to traditional risks like type 2 diabetes mellitus and cardiovascular disease.
Ahmed Farid, Gadelmawla, Noha, Hammad, Karim, Atta, Ahmed, Diaa, Fatma, Abouzkaly, Kriti, Soni, Raveena, Kelkar, Siddharth P, Agrawal, Raheel, Ahmed, Hritvik, Jain, Siddhant, Passey, Wilbert S, Aronow   +11 more
openaire   +2 more sources

Cagrilintide-semaglutide (CagriSema) versus semaglutide or cagrilintide in people with type 2 diabetes (REIMAGINE 2): a double-blind, randomised, controlled, phase 3 study.

Lancet Diabetes and Endocrinology,the
John B Buse, Harpreet S Bajaj, Stine-Mathilde Dalskov, Lucienne Donaldson, Helene H Hansen Duus, Therese Wilbek Fabricius, Martin Haluzík, Ildiko Lingvay, Sue D Pedersen, Richard E Pratley, Akshay B Jain   +10 more
exaly   +2 more sources

Ease of Use, Ease of Learning, and Convenience of the CagriSema Dual-Chamber Pen: Results From a Usability Study in Adults With Overweight, Obesity, or Type 2 Diabetes

Journal of Diabetes Science and Technology
This study evaluated the usability of the CagriSema dual-chamber pen, a single-dose, single-use, pre-filled autoinjector for once-weekly subcutaneous administration of a fixed-dose combination of cagrilintide and semaglutide. Adults with overweight/obesity (n = 85) or type 2 diabetes (n = 65) performed simulated injections after standardized training ...
Walter Gulisano, Gitte Ter-Borch, Paul Brown, Joshua Buron Feinberg, Maya Gonczi, Emily Hildebrand, Gina Legere-DeJohn, Riia Sustarsic, Thomas Sparre   +8 more
openaire   +1 more source

1693-P: Cagrisema-Induced Weight Loss in Diet-Induced Obese Rats Relies on Preserved Mitochondrial Leak Respiration in Skeletal Muscle

Diabetes
Introduction and Objective: Weight management and maintenance is challenged by counter-regulatory mechanisms causing weight regain. One of these mechanisms is a reduction in resting energy expenditure beyond what is explained by the lost weight (termed metabolic adaptation).
IDA BLOM, JULIE JACOBSEN, ANNA T. HOELKER, BARBARA D. EIRIKSFOSS, KRISTINE K. LANGE, JESPER HAVELUND, KIRSTEN RAUN, MARTIN HEY-MOGENSEN, NILS J. FÆRGEMAN, ANNA SECHER, RUNE E. KUHRE, STEEN LARSEN, JENS F. HALLING   +12 more
openaire   +1 more source